268 related articles for article (PubMed ID: 29271815)
1. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
Felipe CR; Oliveira NI; Hannun PG; de Paula MI; Tedesco-Silva H; Medina-Pestana JO
Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
[TBL] [Abstract][Full Text] [Related]
3. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
[TBL] [Abstract][Full Text] [Related]
5. Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Goto N; Ichimori T; Narumi S; Watarai Y
Int Immunopharmacol; 2019 Oct; 75():105772. PubMed ID: 31376625
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
8. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
11. Renal Function Changes Under Everolimus Plus Cyclosporine or Everolimus Plus Tacrolimus After Heart Transplantation.
Chiang TY; Tsao CI; Wang SS
Transplant Proc; 2018 Nov; 50(9):2756-2758. PubMed ID: 30401391
[TBL] [Abstract][Full Text] [Related]
12. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
[TBL] [Abstract][Full Text] [Related]
13. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
[TBL] [Abstract][Full Text] [Related]
14. Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFNγ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation.
Iwasaki K; Kitahata N; Miwa Y; Uchida K; Matsuoka Y; Horimi K; Kobayashi T
Ther Drug Monit; 2019 Jun; 41(3):371-375. PubMed ID: 30939587
[TBL] [Abstract][Full Text] [Related]
15. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of factors influencing the ratio of the trough blood concentration to dose level of everolimus in Japanese kidney transplant recipients.
Geka Y; Hamada Y; Fuchinoue S; Kimura T
Transpl Immunol; 2022 Aug; 73():101609. PubMed ID: 35500848
[TBL] [Abstract][Full Text] [Related]
17. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
Manzia TM; Angelico R; Toti L; Grimaldi C; Sforza D; Vella I; Tariciotti L; Lenci I; Breshanaj G; Baiocchi L; Tisone G
Transplant Proc; 2018; 50(1):175-183. PubMed ID: 29407305
[TBL] [Abstract][Full Text] [Related]
18. Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).
Relbo Authen A; Grov I; Karason K; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Dellgren G; Solbu D; Arora S; Andreassen AK; Gullestad L
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640529
[TBL] [Abstract][Full Text] [Related]
19. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation.
Yamanaka K; Kakuta Y; Nakazawa S; Kato T; Abe T; Imamura R; Okumi M; Ichimaru N; Kyo M; Kyakuno M; Takahara S; Nonomura N
Transplant Proc; 2016 Apr; 48(3):781-5. PubMed ID: 27234735
[TBL] [Abstract][Full Text] [Related]
20. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]